WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH) (OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2023.
Quarter and Year Ended December 31, 2023 Highlights:
Financial Results
Net AGGRASTAT product sales for the year ended December 31, 2023, were $9.7 million compared to $11.7 million for the year ended December 31, 2022. The decrease in AGGRASTAT® revenues compared to the previous year is the result of a decrease in the volume of AGGRASTAT® sold and pricing competition from generic tirofiban.
ZYPITAMAG through insured channels contributed $2.4 million of revenue for the year ended December 31, 2023 compared to $3.6 million for the year ended December 31, 2022. The decrease in revenue through insured channels is primarily as a result of higher wholesaler fees and coverage gap payments, and lower reimbursement from pharmacy benefit managers. This amount does not include sales of ZYPITAMAG® through the Marley Drug business.
The Marley Drug business contributed $9.6 million of revenue for the year ended December 31, 2023 compared to $7.8 million for the year ended December 31, 2022. Marley Drug is a US pharmacy licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico. It serves thousands of customers and provides another channel for direct-to-consumer marketing, distribution and improved profit margin for ZYPITAMAG. The increase in revenue is a result of increased sales through marketing, fulfillment partnerships, its e-commerce platform, and increased sales of ZYPITAMAG.
Adjusted EBITDA for the year ended December 31, 2023 was $1.9 million compared to $3.3 million for the year ended December 31, 2022. Decreased adjusted EBITDA for the year ended December 31, 2023 resulted from lower AGGRASTAT net revenue and higher cost of goods, partially offset by lower R&D expenses.
Net loss for the year ended December 31, 2023 was $922,000 or $0.09 per share compared to a net income of $1.4 million or $0.13 per share for the year ended December 31, 2022. The main factors contributing to the net loss recorded for the year ended December 31, 2023 were lower net revenue and higher selling expenses, partially offset by lower R&D expenses.
At December 31, 2023, the Company had unrestricted cash totaling $6.4 million, up from $4.9 million of unrestricted cash held as of December 31, 2022. Cash flows from operating activities for the year ended December 31, 2023 totaled $2.1 million compared to $1.8 million for the year ended December 31, 2022.
All amounts referenced herein are in Canadian dollars unless otherwise noted.
The Company plans to hold an investor conference call in May 2024 to present the results for the three months ended March 31, 2024 with date and dial in information to be provided. The full financial statements are available at www.sedar.com and on the Company's website at www.medicure.com.
Notes
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email This email address is being protected from spambots. You need JavaScript enabled to view it.. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastathdb.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To receive investor and business updates from Medicure, please fill out this form click here to be added to Medicure's e-mail list.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information
Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.medicure.com
Consolidated Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
As at December 31 | 2023 | 2022 | ||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 6,369 | $ | 4,857 | ||||
Accounts receivable | 4,794 | 5,635 | ||||||
Inventories | 2,900 | 3,221 | ||||||
Prepaid expenses | 1,143 | 1,134 | ||||||
Total current assets | 15,206 | 14,847 | ||||||
Non-current assets: | ||||||||
Property and equipment | 736 | 1,187 | ||||||
Intangible assets | 8,940 | 10,624 | ||||||
Goodwill | 3,102 | 3,177 | ||||||
Other assets | 75 | 63 | ||||||
Total non-current assets | 12,853 | 15,051 | ||||||
Total assets | $ | 28,059 | $ | 29,898 | ||||
Liabilities and Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 7,603 | $ | 7,128 | ||||
Royalty obligation | - | 179 | ||||||
Acquisition payable | - | 677 | ||||||
Income taxes payable | 16 | 60 | ||||||
Current portion of lease obligations | 315 | 346 | ||||||
Total current liabilities | 7,934 | 8,390 | ||||||
Non-current liabilities | ||||||||
Lease obligations | 229 | 503 | ||||||
Total non-current liabilities | 229 | 503 | ||||||
Total liabilities | 8,163 | 8,893 | ||||||
Equity: | ||||||||
Share capital | 81,014 | 80,917 | ||||||
Contributed surplus | 10,723 | 10,476 | ||||||
Accumulated other comprehensive loss | (5,989 | ) | (5,458 | ) | ||||
Deficit | (65,852 | ) | (64,930 | ) | ||||
Total equity | 19,896 | 21,005 | ||||||
Total liabilities and equity | $ | 28,059 | $ | 29,898 | ||||
Consolidated Statements of Net (Loss) Income and Comprehensive (Loss) Income
(expressed in thousands of Canadian dollars, except per share amounts)
For the year ended December 31 | 2023 | 2022 | 2021 | |||||||||
Revenue, net | ||||||||||||
Product sales, net | $ | 21,694 | $ | 23,065 | $ | 21,744 | ||||||
Cost of goods sold | 7,705 | 6,990 | 9,032 | |||||||||
Gross profit | 13,989 | 16,075 | 12,712 | |||||||||
Expenses | ||||||||||||
Selling | 8,306 | 7,935 | 10,312 | |||||||||
General and administrative | 4,131 | 4,193 | 2,697 | |||||||||
Research and development | 2,406 | 2,754 | 1,796 | |||||||||
| 14,843 | 14,882 | 14,805 | ||||||||||
Other Income: | ||||||||||||
Other Income | - | (346 | ) | (1,828 | ) | |||||||
| - | (346 | ) | (1,828 | ) | ||||||||
Finance costs: | ||||||||||||
Finance (income) expense, net | (65 | ) | 206 | 525 | ||||||||
Foreign exchange loss (gain), net | 108 | (52 | ) | (31 | ) | |||||||
| 43 | 154 | 494 | ||||||||||
Net (loss) income before income taxes | $ | (897 | ) | $ | 1,385 | $ | (759 | ) | ||||
Income tax recovery (expense) | ||||||||||||
Current | (25 | ) | (20 | ) | 32 | |||||||
Deferred | - | - | - | |||||||||
| (25 | ) | (20 | ) | 32 | ||||||||
Net (loss) profit | $ | (922 | ) | $ | 1,365 | $ | (727 | ) | ||||
Item that may be reclassified to profit or loss | ||||||||||||
Exchange differences on translation of foreign subsidiaries: | (531 | ) | 1,182 | (143 | ) | |||||||
Comprehensive Income (loss) | $ | (1,453 | ) | $ | 2,547 | $ | (870 | ) | ||||
Earnings (loss) per share | ||||||||||||
Basic | $ | (0.09 | ) | $ | 0.13 | $ | (0.07 | ) | ||||
Diluted | $ | (0.09 | ) | $ | 0.13 | $ | (0.07 | ) | ||||
Consolidated Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
For the year ended December 31 | 2023 | 2022 | 2021 | |||||||||
Cash (used in) provided by: | ||||||||||||
Operating activities: | ||||||||||||
Net (loss) profit for the year | $ | (922 | ) | $ | 1,365 | $ | (727 | ) | ||||
Adjustments for: | ||||||||||||
Current income tax expense (recovery) | 25 | 20 | (32 | ) | ||||||||
Amortization of property and equipment | 434 | 461 | 406 | |||||||||
Amortization of intangible assets | 1,736 | 1,594 | 2,739 | |||||||||
Share-based compensation | 288 | 47 | 135 | |||||||||
Write-down of inventories | 277 | 38 | 1,339 | |||||||||
Change in fair value of contingent consideration | - | (346 | ) | (1,803 | ) | |||||||
Finance (income) expense, net | (65 | ) | 190 | 525 | ||||||||
Unrealized foreign exchange loss (gain) | 108 | (52 | ) | (31 | ) | |||||||
Change in the following: | ||||||||||||
Accounts receivable | 969 | (864 | ) | 593 | ||||||||
Inventories | (31 | ) | 166 | 471 | ||||||||
Prepaid expenses | (26 | ) | (194 | ) | 305 | |||||||
Other assets | - | (2 | ) | 99 | ||||||||
Accounts payable and accrued liabilities | 86 | 568 | 20 | |||||||||
Interest received (paid), net | 48 | (16 | ) | 49 | ||||||||
Income taxes paid, net | (61 | ) | (91 | ) | - | |||||||
Royalties paid | (256 | ) | (1,056 | ) | (99 | ) | ||||||
Cash flows from operating activities | 2,079 | 1,828 | 3,989 | |||||||||
Investing activities: | ||||||||||||
Repayment of holdback payable | - | - | (1,876 | ) | ||||||||
Acquisition of property and equipment | - | (14 | ) | (377 | ) | |||||||
Acquisition of intangible assets | (270 | ) | (296 | ) | (441 | ) | ||||||
Cash flows (used in) from investing activities | (270 | ) | (310 | ) | (2,694 | ) | ||||||
Financing activities: | ||||||||||||
Repayment of lease liability | (353 | ) | (355 | ) | (316 | ) | ||||||
Stock options exercised | 56 | - | - | |||||||||
Cash flows used in financing activities | (297 | ) | (355 | ) | (316 | ) | ||||||
Foreign exchange loss on cash held in foreign currency | - | - | (1 | ) | ||||||||
Increase (decrease) in cash | 1,512 | 1,163 | 978 | |||||||||
Cash and cash equivalents, beginning of period | 4,857 | 3,694 | 2,716 | |||||||||
Cash and cash equivalents, end of year | $ | 6,369 | $ | 4,857 | $ | 3,694 | ||||||
| Last Trade: | C$0.88 |
| Daily Volume: | 0 |
| Market Cap: | C$9.190M |
August 14, 2024 June 24, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
